Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Treatment in Patients Suffering From Chronic Fibrosing ILD With a Progressive Phenotype
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases; Pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms INREAL
- Sponsors Boehringer Ingelheim
- 12 Jul 2024 Status changed from active, no longer recruiting to completed.
- 10 Jun 2024 Planned End Date changed from 30 May 2024 to 30 Jun 2024.
- 22 May 2024 Results assessing changes in FVC and in cough or dyspnea symptom scores of the Living with Pulmonary Fibrosis (L-PF) questionnaire after initiation of nintedanib treatment according to standard of care in a real-world population of PF-ILD / PPF patients presented at the 120th International Conference of the American Thoracic Society.